Trulieve Cannabis Corp. (TRLV)
Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.
Sector: Medicinal Chemicals & Botanical Products
Industry: Drug Manufacturers - Specialty & Generic
Trulieve Cannabis Corp.
NYSE:TRLVHealthcare · Drug Manufacturers - Specialty & Generic
-4.58%$10.42
AH Close$10.42+0.00%vs close
AH Close$10.42+0.00%vs close
Mkt Cap$2.01B
Float188.56M
O/S192.57M
Inst Own18.2%
SI3.4%
Dilution
Delisting Issues Timeline
Financials Summary
Revenue$1.18B
Net Income-$116.38M
Total Assets$2.7B
Free Cash Flow$212.31M
Debt & Equity
Debt 33%
Equity 67%
Total Debt$563.62M
Total Equity$1.16B
Shares Outstanding
Short Interest
Split History
No splits on record
Nothing in TRLV's public trading history: no forward or reverse split has affected the share count.
Balance Sheet Details
Assets$2.7B
Liabilities$1.55B
Accounts Receivable$20.2M
Accounts Payable$26.78M
Inventory$242.3M
PP&E (Net)$838.74M
Goodwill$483.9M
Intangible Assets$798.37M
Income Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Revenue | $1.18B |
| YoY Growth | - |
| Cost of Revenue | $470.01M |
| Gross Profit | $711.17M |
| Gross Margin | 60.2% |
| Research and Development | $0 |
| Selling, General, and Administrative | $445.21M |
| Other | $117.63M |
| Total Operating Expenses | $562.85M |
| Operating Income (EBIT) | $148.32M |
| Operating Margin | 12.6% |
| Interest Expense | $63.45M |
| Interest Income | $14.52M |
| Other Income (Expense) | -$56.85M |
| Income Before Tax (EBT) | $91.47M |
| Income Tax Expense | $208.11M |
| Net Income | -$116.38M |
| Net Income Margin | -9.9% |
| Supplementary Data | |
| EPS | -0.61 |
| Diluted EPS | -0.61 |
| Weighted Average OS | 191.30M |
| EBITDA | $328.33M |
| EBITDA Margin | 27.8% |
Balance Sheet
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Assets | |
| Current Assets | |
| Cash and Cash Equivalents | $255.53M |
| Short-Term Investments | $0 |
| Cash and Short-Term Investments | $255.53M |
| Accounts Receivable | $20.2M |
| Inventory | $242.3M |
| Other Current Assets | $26.36M |
| Total Current Assets | $562.72M |
| Long-Term Assets | |
| Property, Plant & Equipment Net | $838.74M |
| Goodwill | $483.9M |
| Intangible Assets | $798.37M |
| Long-Term Investments | $0 |
| Deferred Tax Assets | $0 |
| Other Long-Term Assets | $12.38M |
| Total Long-Term Assets | $2.13B |
| Other Assets | $0 |
| Total Assets | $2.7B |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | $26.78M |
| Short-Term Debt | $4.08M |
| Current Income Tax Payable | $10.16M |
| Current Unearned Revenue | $9.59M |
| Other Current Liabilities | $25.73M |
| Total Current Liabilities | $126.94M |
| Long-Term Liabilities | |
| Long-Term Debt | $227.58M |
| Long-Term Unearned Revenue | $0 |
| Long-Term Deferred Tax Liabilities | $177.99M |
| Other Long-Term Liabilities | $714.77M |
| Total Long-Term Liabilities | $1.43B |
| Other Liabilities | $0 |
| Total Liabilities | $1.55B |
| Stockholders' Equity | |
| Preferred Stock | $0 |
| Common Stock | $0 |
| Retained Earnings | -$912.13M |
| Comprehensive Income & Other | $0 |
| Other Stockholders' Equity | $2.07B |
| Total Equity | $1.16B |
| Minority Interest | -$18.22M |
| Total Liabilities and Equity | $2.71B |
| Supplementary Data | |
| Total Debt | $563.62M |
| Net Debt | $308.09M |
Cash Flow Statement
| Period | FY 2025 |
|---|---|
| Currency | USD |
| Period Ending | 2025-12-31 |
| Operating Activities | |
| Net Income | -$122.25M |
| Depreciation & Amortization | $173.4M |
| Deferred Income Tax | -$18.55M |
| Stock-Based Compensation | $20.47M |
| Changes in Working Capital: | |
| Accounts Receivable | -$3.72M |
| Inventory | -$10.93M |
| Accounts Payable | -$11.26M |
| Other Working Capital | $214.08M |
| Total Working Capital Change | $188.17M |
| Other Non-Cash Items | $31.59M |
| Net Cash from Operating | $272.82M |
| Investing Activities | |
| Capital Expenditures | -$44.19M |
| Acquisitions | $0 |
| Purchases of Investments | $0 |
| Sales of Investments | $60M |
| Other Investing Activities | -$2.31M |
| Net Cash from Investing | $13.5M |
| Financing Activities | |
| Debt Repaid | $393.35M |
| Common Stock Issuance | $140M |
| Common Stock Repurchases | $0 |
| Dividends Paid | $0 |
| Other Financing Activities | -$17.15M |
| Net Cash from Financing | -$270.5M |
| Forex Effect | $0 |
| Net Change in Cash | $15.82M |
| Supplementary Data | |
| Operating Cash Flow | $272.82M |
| Capital Expenditure | -$60.51M |
| Free Cash Flow | $212.31M |
| Cash at Beginning | $239.71M |
| Cash at End | $255.53M |